Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Network Gr. in Skin Health, Bone Health, and Muscular Dyst. - Muscular Dystrophy

Children's Hospital of Eastern Ontario Research Institute Inc

$1,000,000.00

NMD4C: the neuromuscular network for Canada

EF 2022-23

Résumé
Neuromuscular disorders (NMDs) are rare genetic conditions that affect the skeletal muscles, nerves controlling the muscles, or junctions between muscle and nerve. They affect over 64,000 Canadians, 40% of whom are children, and result in lifelong disability, decreased wellbeing and shortened life expectancy. Research has transformed our ability to diagnose and treat NMDs, but their rarity and diversity means that networking and collaboration is essential to continued progress. In 2020, with a three-year grant from CIHR and Muscular Dystrophy Canada (MDC), we launched NMD4C, a pan-Canadian network of clinical, scientific and patient experts. We developed research resources, launched specialist training and education, provided leadership and advocacy to improve access to treatments, and engaged with patient partners to improve care, research, and collaboration. For the next phase of NMD4C, we have partnered with MDC to address emerging challenges and continue to fulfil our mission to improve NMD care and treatment for all Canadians. In this new application, we are bringing together an expanded group of patient partners, clinicians, and researchers with a research plan that will: 1) Strengthen cutting-edge preclinical research through new ways to exchange protocols and expertise and training young scientists in new technologies; 2) Increase clinical research capacity in Canada by developing a national clinical trial network and uniting local efforts in outcome measure and natural history research; 3) Improve NMD care and treatment access by developing a new community of practice, research addressing post-marketing challenges including health economics, drug access and real-world evidence, and educating NMD specialists and equipping them to apply emerging knowledge and tools. These goals will be achieved by: 4) Providing a Canada-wide platform for communication and best-practice sharing to sustain a supportive, collaborative, networked community of NMD stakeholders.
Programme
Network Gr. in Skin Health, Bone Health, and Muscular Dyst. - Muscular Dystrophy
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
481680
Name
Lochmüller Hanns
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Network Grants in Skin Health, Bone Health, and Muscular Dystrophy
Projecttitle
NMD4C: the neuromuscular network for Canada
Programtype2
Operating Grants
Orgnameinp2
Children's Hospital of Eastern Ontario Research Institute Inc
Cihramount2
$1,000,000
Cihrequipment2
$0
Programname2
Network Gr. in Skin Health, Bone Health, and Muscular Dyst. - Muscular Dystrophy
Keyworddelim
Clinical Trial Networks; Networks; Neuromuscular Disease; Open Science; Patient Partnerships; Preclinical Research Resources; Training And Education; Translational Research
Abstract
Neuromuscular disorders (NMDs) are rare genetic conditions that affect the skeletal muscles, nerves controlling the muscles, or junctions between muscle and nerve. They affect over 64,000 Canadians, 40% of whom are children, and result in lifelong disability, decreased wellbeing and shortened life expectancy. Research has transformed our ability to diagnose and treat NMDs, but their rarity and diversity means that networking and collaboration is essential to continued progress. In 2020, with a three-year grant from CIHR and Muscular Dystrophy Canada (MDC), we launched NMD4C, a pan-Canadian network of clinical, scientific and patient experts. We developed research resources, launched specialist training and education, provided leadership and advocacy to improve access to treatments, and engaged with patient partners to improve care, research, and collaboration. For the next phase of NMD4C, we have partnered with MDC to address emerging challenges and continue to fulfil our mission to improve NMD care and treatment for all Canadians. In this new application, we are bringing together an expanded group of patient partners, clinicians, and researchers with a research plan that will: 1) Strengthen cutting-edge preclinical research through new ways to exchange protocols and expertise and training young scientists in new technologies; 2) Increase clinical research capacity in Canada by developing a national clinical trial network and uniting local efforts in outcome measure and natural history research; 3) Improve NMD care and treatment access by developing a new community of practice, research addressing post-marketing challenges including health economics, drug access and real-world evidence, and educating NMD specialists and equipping them to apply emerging knowledge and tools. These goals will be achieved by: 4) Providing a Canada-wide platform for communication and best-practice sharing to sustain a supportive, collaborative, networked community of NMD stakeholders.
Competitiondate
202301
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Lochmüller, Hanns; Osman, Homira; Brais, Bernard; Campbell, Craig Gordon N; Chang, Natasha C; Dowling, James; Gagnon, Cynthia; Gonorazky, Hernan D; Hodgkinson, Victoria; Karamchandani, Jason; Korngut, Lawrence W; Kothary, Rashmi K; Mah, Jean K; O'Connell, Colleen; Patten, Kessen; Rossi, Fabio M; Schellenberg, Kerri; Selby, Kathryn A; Warman Chardon, Jodi
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,000,000~ $0~